Inari Medical, Inc. (NASDAQ:NARI) Receives Consensus Rating of “Hold” from Analysts

Shares of Inari Medical, Inc. (NASDAQ:NARI) have received a consensus recommendation of “Hold” from the fourteen ratings firms that are presently covering the stock, Marketbeat reports. Twelve equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $68.00.

A number of analysts recently weighed in on the stock. Truist Financial increased their price objective on shares of Inari Medical from $50.00 to $63.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. William Blair restated a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Baird R W downgraded Inari Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 7th. Oppenheimer started coverage on shares of Inari Medical in a research note on Tuesday, December 17th. They issued an “outperform” rating and a $75.00 price target on the stock. Finally, Piper Sandler upped their target price on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 7th.

Inari Medical Stock Performance

Shares of NARI opened at $79.97 on Friday. The company’s fifty day simple moving average is $79.86 and its 200-day simple moving average is $61.08. The company has a market cap of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02. Inari Medical has a twelve month low of $36.73 and a twelve month high of $79.99.

Insider Transactions at Inari Medical

In other Inari Medical news, Director William Hoffman sold 200,000 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the sale, the director now owns 238,987 shares of the company’s stock, valued at approximately $14,451,543.89. The trade was a 45.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 10.60% of the company’s stock.

Institutional Investors Weigh In On Inari Medical

A number of large investors have recently made changes to their positions in NARI. Vestal Point Capital LP raised its position in Inari Medical by 342.9% during the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock worth $63,922,000 after buying an additional 1,200,000 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Inari Medical in the 3rd quarter worth about $1,397,000. Verition Fund Management LLC purchased a new position in shares of Inari Medical during the 3rd quarter valued at approximately $1,235,000. Jane Street Group LLC grew its position in shares of Inari Medical by 32.4% in the third quarter. Jane Street Group LLC now owns 95,223 shares of the company’s stock valued at $3,927,000 after purchasing an additional 23,286 shares during the period. Finally, Intech Investment Management LLC acquired a new stake in Inari Medical in the 3rd quarter worth about $716,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.